News & Updates

Show Multimedia Only

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

A 12-month therapeutic intervention with self-administered abatacept can delay the onset of rheumatoid arthritis (RA) in at-risk individuals for up to 4 years, according to results from the ALTO follow-up study presented at EULAR 2025.

RA onset delayed through 4 years with 1-year abatacept treatment in at-risk individuals

a day ago

Novel adaptor enhances care for patients on NIV

12 Jul 2025 by

A new tube and inhaler adaptor (TIA) has been developed to improve the management of patients receiving noninvasive ventilation (NIV), and this device can be used across diverse clinical settings.

Novel adaptor enhances care for patients on NIV

12 Jul 2025

Depression tied to increased mortality in IPF

12 Jul 2025

Patients with idiopathic pulmonary fibrosis (IPF) and comorbid depression are less likely to initiate antifibrotic treatment and thus face an increased risk of death, as reported in a study.

Depression tied to increased mortality in IPF

12 Jul 2025

Nerandomilast safe, effective in autoimmune disease-related PPF

11 Jul 2025 by

Treatment with nerandomilast demonstrates efficacy in slowing forced vital capacity (FVC) decline in patients with autoimmune interstitial lung disease (ILD) similar to that seen in the overall trial population, reveals a subgroup analysis of the FIBRONEER-ILD study.

Nerandomilast safe, effective in autoimmune disease-related PPF

11 Jul 2025

Nerandomilast slows IPF progression in patients already on antifibrotic therapy

11 Jul 2025 by

The novel oral PDE4B* inhibitor nerandomilast slows the progression of idiopathic pulmonary fibrosis (IPF) in patients receiving antifibrotic treatment, as shown in the phase III FIBRONEER-IPF trial.

Nerandomilast slows IPF progression in patients already on antifibrotic therapy

11 Jul 2025

More cognitive issues, fewer heart problems after COVID-19 vs flu hospitalization in Asians

04 Jul 2025 by

Individuals hospitalized for COVID-19 vs seasonal influenza face a greater risk of cognitive impairment and fatigue but a lower risk of cardiac disorders as long-term consequences of infection, according to a retrospective population-based cohort study in Singapore.

More cognitive issues, fewer heart problems after COVID-19 vs flu hospitalization in Asians

04 Jul 2025

Wildfire smoke exposure ups risk of heart failure in older adults

03 Jul 2025

Exposure to wildfire smoke for an extended period may increase the risk of heart failure (HF) in older adults, particularly women and socially vulnerable populations, suggests a study.

Wildfire smoke exposure ups risk of heart failure in older adults

03 Jul 2025

Short-course antibiotic for paediatric CAP on par with long-course regimen

02 Jul 2025

A short-course antibiotic treatment for children with community-acquired pneumonia (CAP) demonstrates effectiveness similar to the long-course regimen but with fewer serious adverse events (AEs), reports a study.